Introduction
TAM is a selective estrogen receptor modulator (SERM) and is the most firmly established adjuvant endocrine therapy for pre-and postmenopausal women with breast cancer. The binding of TAM and its metabolites to the ER induces a conformation change in the three-dimensional structure of the ER, which prevents the receptor from agonist conformation associated with estrogen-induced genomic signaling. Therefore, TAM binding interferes with the transcription process, inhibits estrogen activity and suppresses the growth of hormonedependent breast cancer cells to combat breast cancer. 1 TAM is a pro-drug that has relatively poor affinity for the ER. Liver enzymes metabolize TAM into several metabolites. Cytochrome P450 3A4 (CYP3A4) primarily produces the major metabolite N-desmethyltamoxifen, which also has low affinity for the ER. 2 Cytochrome P450 2D6 (CYP2D6) predominantly produces 4-hydroxy-N-desmethyltamoxifen (endoxifen) and partially participates in the production of 4-hydroxytamoxifen (4OHtam), and these two metabolites have much greater affinity for the ER than TAM or N-desmethyltamoxifen.
concentrations of TAM active metabolites are associated with the CYP2D6 genotype. CYP2D6 poor metabolizers (PMs) contain two null alleles, which produce the lowest plasma active metabolite concentrations. CYP2D6 ultrarapid metabolizers (UMs) carry duplicated or multi-duplicated gene copies of the same allele, which enhances enzymatic activity and produces the highest concentrations of active metabolite in plasma. 4 Jin et al. 3 investigated the plasma concentrations of endoxifen in 80 breast cancer patients. The plasma concentrations of endoxifen in patients who were homozygous, with two null alleles, and heterozygous, with one null allele, were significantly lower after 4 months of TAM treatment than in patients who carried two functional alleles.
The CYP2D6 gene is extremely polymorphic. CYP2D6*4 occurs most frequently in Caucasians with an allele frequency of 20-25% and is responsible for 70-90% of all PMs. 5 The rs1065852, also known as CYP2D6*10 (c.100C>T), is the most common polymorphism in Asian populations and has a frequency of 30-50% in Chinese populations. 6, 7 Goetz et al.
8
first reported the relationship between CYP2D6 polymorphisms and the AM efficacy in a phase III clinical trial. They found that patients with the CYP2D6*4 genotype had a poor prognosis. A retrospective study in China 9 demonstrated that women with breast cancer with the CYP2D6*10 allele had a lower plasma concentration of 4-hydroxy-tamoxifen, and the CYP2D6*10 allele interfered with the TAM treatment outcome. Another study retrieved data from72 TAM-treated early breast cancer patients and demonstrated that the homozygous variant T/T genotype was a negative prognostic factor in young breast cancer patients using TAM. 10 Several studies examined initial adjuvant endocrine treatment with TAM or AIs. These trials demonstrated that AIs were superior to TAM in adjuvant endocrine therapy of postmenopausal women with hormone receptor-positive breast cancer. [11] [12] [13] Therefore, the use of AIs was recommended as an adjuvant endocrine treatment in postmenopausal women. The CYP2D6 enzyme does not metabolized these drugs, which makes AIs immune to the influence of CYP2D6 polymorphisms.
The efficacy of the standard TAM adjuvant treatment for Chinese premenopausal breast cancer patients with variations in the CYP2D6 allele might not be as good as we thought. We reviewed the related literature and selected the following different SNPs in the CYP2D6 gene: *10 (rs1065852, 100C>T), *2 A (rs16947, 2850C>T), rs1135840 (4180G>C), rs1080989 (1000G>A), rs28680494 (2057G>T), *82 (rs76187628, 1014T>C), *90 (1693A>G), *91 (1984G>A) and *94 (3181A>G). Our study was performed in early hormone receptor (HR)-positive breast cancer women to validate the association between these CYP2D6 genotypes and the outcomes of patients who received TAM.
Materials and Methods

Study population
A total of 778 patients with primary breast cancer who received adjuvant TAM (n 5 325) or AIs (n 5 453) treatment after completion of primary surgery at the National Cancer Center in China from June 1991 through March 2014 were included in our study. The following inclusion criteria were used: (1) diagnosed with invasive breast cancer; (2) estrogen receptor (ER) and/or progesterone receptor (PR) positive on immunohistochemistry (IHC) and (3) TAM (20 mg/day orally) or AIs (40 mg/day orally) initiated as a standard adjuvant therapy after surgery for 5 years, and TAM or AIs was stopped when a recurrence was identified.
The median follow-up was 75.6 months (range: 1.6-251.1 months). DFS was defined as the time from surgery to recurrence or death. The following clinicopathological data were collected: age at diagnosis, tumor grade, T stage, N stage, clinical stage (AJCC 7th ed.), adjuvant chemotherapy, adjuvant radiotherapy and ER, PR, human epidermal growth factor receptor-2 (HER2) status. All patients underwent standard surgery and follow-up treatments, such as chemotherapy, endocrine therapy and radiotherapy, according to NCCN guidelines.
Two pathologists confirmed all of the pathological and IHC assessments, which were performed according to typical standards.
Peripheral blood samples were used as a source of DNA for CYP2D6 genotyping.
Genotyping
We selected known clinical drug-response variants of CYP2D6 SNPs from an online database (www.cypalleles.ki.se). We also used the dbSNP database (www.ncbi.nlm.nih.gov) and found three potential functional SNPs in the promoter region. We screened candidate SNPs with minor allele frequencies of >5% in Chinese population using the 1000Genomes database
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(www.internationalgenome.org). We used Haploview software 4.2 to analyze the linkage disequilibrium (LD) of candidate SNP based on the CHB data of 1000Genomes database. Other SNPs of r2 5 1 were abandoned. The following SNPs were selected: *10 (rs1065852, 100C>T), *2 A (rs16947, 2850C>T), rs1135840 (4180G>C), rs1080989 (1000G>A), rs28680494 (2057G>T), *82 (rs76187628, 1014T>C), *90 (1693A>G), *91 (1984G>A) and *94 (3181A>G). DNA was extracted from peripheral blood samples. Genotypes were detected using the MassArray system (Agena, San Diego, CA). We isolated approximately 10-20 ng of genomic DNA from peripheral blood. Sample DNA was amplified using a multiplex polymerase chain reaction (PCR) reaction. Assay design 3.1 software (Agena) was used to design the primers. The following primers were used for CYP2D6*10: forward: 5 0 -ACGTTGGATGTGGTCGAAGCAGTATGGTGT-3 0 and reverse: 5 0 -ACGTTGGATGTATGGGGCTAGAAGCACTGG-3 0 . The PCR products were used for a locus-specific single-base extension reaction, and the unextension primer used was as follows: 5 0 -GATGGGCTGCACGCTAC-3 0 . The resulting products were desalted and transferred to a 384-element SpectroCHIP array. The alleles were discriminated using mass spectrometry (Agena). Table 1 lists all of the primers and unextension primers used for the SNPs.
Statistical analysis
Correlation between the genotype variants and clinicopathological characteristics was determined using Pearson's v 2 test.
Survival curves were estimated using the Kaplan-Meier method, and the curves were compared using log-rank tests. A Cox regression model was used to determine whether a factor was an independent predictor of survival in multivariate analysis. All statistical tests were two-sided, and p-values <0.05 were considered statistically significant. Statistical analyses were performed using SPSS 17.0 software. Table 2 lists the frequencies of the CYP2D6 alleles in our study. CYP2D6*10 and rs1080989 were related to survival in Table 1 . Primers and unextension primers used for the SNPs SNPs patients who received TAM, but the other alleles were not related to survival. We tested for the LD between CYP2D6*10 and rs1080989, which yielded an r 2 of 0.98. So the analysis for rs1080989 was skipped. Tests for HardyWeinberg equilibrium (HWE) were done and demonstrated that the most important CYP2D6*10 (p 5 0.510) allele was within HWE, with some deviation for the *2 A (p < 0.001), rs1135840 (p < 0.001), rs1080989 (p 5 0.002), rs28680494 (p 5 0.001) and *82 (p < 0.001).
Results
Frequencies of genotypes
Association between the CYP2D6*10 genotype and survival in patients who received TAM or AIs treatment The CYP2D6*10 (c.100C>T) genotype was assessed in all patients. A total of234 (30.1%) patients were homozygous for the wild genotype (C/C), 167 (21.5%) patients were homozygous for the variant genotype (T/T), and 377 (48.5%) patients had a heterozygous genotype (C/T). No significant associations between the CYP2D6*10 genotype and age, grade, T stage, N stage, clinical stage, adjuvant chemotherapy, adjuvant radiotherapy or ER or PR and C-erbB2status were found in the 325 patients who received adjuvant TAM treatment ( Table 3 ). The CYP2D6*10 genotype was significantly associated with 5-year DFS in this subgroup. Women with the homozygous variant T/T genotype had a lower 5-year DFS rate than women with the homozygous wild-type C/C or heterozygous C/T genotype (54.9% vs. 70.9%, p 5 0.007) (Fig.  1a) . The 5-year DFS rate in patients with C/T was similar to patients with C/C (70.6% vs. 71.3%, p 5 0.833) (Fig. 1c) . The T/T genotype remained an independent prognostic marker of DFS in multivariate analysis compared to the C/T or C/C genotype (hazard ratio 5 1.87; 95%confidence interval 5 1.19-2.93; p 5 0.006) ( Table 4) after adjusting for age, grade, T stage, N stage, adjuvant chemotherapy, adjuvant radiotherapy, and ER, PR and C-erbB2 status in this patient subgroup. The hazard ratios and p-values for other factors in the multivariate model were presented in Supporting Information  Table S1 . The CYP2D6*10 genotype was not significantly associated with DFS in the subgroup of women who received AIs (p 5 0.332) (Fig. 1b) . Cancer Therapy and Prevention
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Discussion
Adjuvant TAM treatment in women with ER-positive breast cancer decreased the annual odds of recurrence by 39% and the annual odds of death by 31%. 14 AIs provided better survival results in adjuvant treatment compared to TAM in postmenopausal women. 11 Therefore, 5-year postoperative treatment with TAM is considered as a standard method for adjuvant endocrine therapy in early premenopausal ER-positive breast cancer patients. The latest epidemiological data in China revealed that breast cancer was the most frequently diagnosed cancer in women. The National Cancer Center estimated that 272,400 Chinese would be diagnosed with breast cancer and that 70,700 would die of the disease in China in 2015. 15 Most Western breast cancer women were postmenopausal. The rate of premenopausal breast cancer patients was higher in China. Therefore, TAM was more frequently used, and the impact of the CYP2D6 genotype was much larger in Chinese breast cancer patients.
The CYP2D6*10 genotype was the most common polymorphism of CYP2D6 in the Chinese population. The frequency of the CYP2D6*10 allele in our study was 45.7%, and the homozygous variant T/T genotype accounted for 21 .5% of all subjects tested, which is consistent with a previous report. 6 Although some small-scale retrospective studies addressed the correlation between the CYP2D6*10 genotype and clinical outcome in Chinese women who received TAM treatment, our sample size was larger.
We found that breast cancer patients with the CYP2D6*10 T/T genotype who received TAM treatment exhibited worse DFS than patients with the wild-type C/C or heterozygous C/T genotype, and the T/T genotype remained an independent poor prognostic factor of DFS in this patient cohort.
We used a control group to investigate the association between the CYP2D6*10 genotype and survival in 453 women who received AIs treatment, which is not metabolized by CYP2D6, to ensure that the CYP2D6*10 genotype was a predictive marker for the effect of TAM treatment, but not a prognosis marker for breast cancer. There was no significant association between the CYP2D6*10 genotype and survival in this subgroup, which indicates that the CYP2D6*10 genotype itself was not a prognostic marker.
Our results are similar to many previous studies. Goetz et al.
8 enrolled a total of 223 patients with ER-positive postmenopausal breast cancer in a phase III clinical trial. These patients received 20 mg of TAM daily. The median length of follow-up was 11.4 years. They found that patients with the CYP2D6*4 genotype had a poor prognosis. The CYP2D6*4 genotype was associated with DFS (p 5 0.012), but exerted no effect on overall survival (OS, p 5 0.169). Schroth et al. 16 enrolled 206 patients who received TAM and 280 patients who did not receive TAM in a retrospective analysis. They found that patients who were CYP2D6 homozygous for two null alleles gad a shorter DFS, but there was no difference in OS. A large-scale retrospective analysis of 1,325 German and US patients who received TAM treatment reported a similar conclusion. 17 Thompson et al. 18 genotyped 33 pairs of CYP2D6 alleles in 618 patients who received TAM treatment and demonstrated that patients with one or more mutated (null or intermediate) CYP2D6 alleles had worse DFS. However, other studies found no association between the CYP2D6 genotype and survival in breast cancer patients treated with TAM. 19, 20 The reason for this discrepancy is not clear, but it may be due to different sample sizes or patient selection.
The SNPs with frequencies above 30% other than CYP2D6*10 included rs1080989, rs28680494, rs1135840 and rs76187628. The rs1080989 and rs28680494 were located in the promoter region of CYP2D6 gene. Through an online tool (https://snpinfo.niehs.nih.gov/), we predicted the rs1080989 and rs28680494 were located within a transcription factor binding site. Their polymorphisms might affect the binding of transcription factors to the gene, resulting in the change of the gene expression and further affecting the biological function. 21 But there were no reports on the functions of these SNPs. The polymorphism of rs1080989 was related to survival in patients who received TAM while rs28680494 was not. We tested for the LD between CYP2D6*10 and rs1080989, which yielded an r 2 of 0.98 indicating they were in strong LD. The association of rs1080989 with efficacy of TAM would be just a consequence of LD to the CYP2D6*10. The rs1135840 and rs76187628 were missense polymorphisms located in the exons of CYP2D6. There were evidences showing the rs1135840 polymorphism could lead to the formation of an unstable enzyme and ultimately resulting in decreased CYP2D6 activity. 22 As for rs76187628, there were still no reports on its function. Our results did not show any correlation between these two SNPs and the efficacy of TAM.
Several studies investigated the relationship between CYP2D6 polymorphisms and the TAM efficacy, but our study was one of the largest studies in China. These results suggested that other treatment like AIs plus ovarian function suppression might be more suitable for those groups with impaired CYP2D6 functionality than TAM.
We note several limitations in our study. First, our study was a retrospective study. Second, other genes, such as CYP2C9 and CYP3A5, may also influence TAM metabolism. 3 We did not determine the impact of these genetic variants in our study because the frequency of these variants is quite rare in Chinese populations. Therefore, our results should be carefully interpreted. In summary, we found that 21.5% of Chinese breast cancer patients had the CYP2D6*10 T/T genotype. Women with this genotype had a worse clinical outcome when receiving TAM treatment. This conclusion may optimize the individualized treatments for this subgroup of patients. Our research team had launched a randomized controlled study to compare AIs/TAM use with ovarian function suppression/ablation in the treatment of premenopausal breast cancer patients with CYP2D6*10 polymorphisms to confirm the present results. Hopefully, the results will change clinical practice in this group of women.
